CYP17 Inhibitors for Prostate Cancer Treatment - An Update
Abstract:It is almost 70 years since the discovery by Huggins et al. that androgens are essential for prostate cancer (PC) growth and progression, and there has been about 30 years experience using ketoconazole for PC theraphy. Since then we have come a long way in learning about the disease and developing new strategies to approach it, among which is cytochrome 17α-hydroxylase-C17,20-lyase (CYP17) inhibition. This review focuses on the efforts to find prospective CYP17 inhibitors, both steroidal and nonsteroidal, in the absence of a 3D structure of the enzyme. It covers almost 4 decades of literature with highlights on the most significant achievements in this area, providing insight into PC pathophysiology, management and treatment options.
Document Type: Research Article
Affiliations: Laboratorio de Quimica Farmaceutica, Faculdade de Farmacia, Universidade de Coimbra, Rua do Norte, 3000-295 Coimbra, Portugal.
Publication date: April 1, 2008
More about this publication?
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.